PROTEINS/cerebrospinal fluid Query Show help

Exact matching

The contribution gives a survey about the problematics of surface tension in biomedical sciences. The paper presents results of a study devoted to the cerebrospinal fluid. The distribution of the surface tension values of this liquid in healthy individuals is presented (n = 33), and further, statistically significant correlations between the cerebrospinal fluid surface tension value and 1. concentration of total proteins expressed by Spearman's coefficient p(s) = (-0.995) and 2. number of cell elements expressed through Spearman's coefficient p(s) = (-0.965) in cerebrospinal fluid are described.

MeSH
Adult MeSH
Glucose cerebrospinal fluid MeSH
Blood Cells cytology MeSH
Middle Aged MeSH
Humans MeSH
Cerebrospinal Fluid chemistry cytology MeSH
Cell Count MeSH
Surface Tension MeSH
Cerebrospinal Fluid Proteins cerebrospinal fluid MeSH
Aged MeSH
Sensitivity and Specificity MeSH
Statistics as Topic MeSH
Check Tag
Adult MeSH
Middle Aged MeSH
Humans MeSH
Male MeSH
Aged MeSH
Female MeSH
Publication type
Journal Article MeSH
Names of Substances
Glucose MeSH
Cerebrospinal Fluid Proteins MeSH

Article

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

... Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects ...

Journal of neurochemistry. 2016 Oct ; 139 Suppl 1 () : 290-317. [epub] 20160210

J Neurochem
ISSN 1471-4159 | 0022-3042
Source

Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. In Alzheimer's disease, levels of increased CSF tau protein and decreased levels of β-amyloid 1-42 (Aβ42) have been shown to correlate with brain plaque formation and tangle pathology. Intracellular Lewy inclusions containing aggregated α-synuclein (α-syn) represent a pathological hallmark of Parkinson's disease (PD). In most - but not all - studies published to date total CSF α-syn concentrations have been found to be decreased in disorders related to α-syn pathology, that is, PD, dementia with Lewy bodies and multiple system atrophy. However, these reports show extensive signal overlap among tested individuals, thereby diminishing its potential for routine use in clinical practice. To investigate potential biological (i.e., non-technical) confounders of reported CSF levels for α-syn, Aβ42, and tau in PD and related disorders, we carried out a methodical review of known factors that underlie signal variability and speculate on those that have not yet been tested. We discuss several biological factors, such as neuropathology, demographics, clinical phenotype, progression and duration of disease, concomitant illnesses and, last but not least, pharmacotherapy, which in isolation or combination can substantially alter values for CSF proteins of interest. Enhanced implementation of standardized clinical protocols, streamlined operating procedures, and further progress in the development of validated assays for CSF proteins have the potential to (i) inform us as to the pathogenesis of disease, (ii) support the laboratory-based diagnosis for symptomatic subjects in the future, and (iii) facilitate breakthrough therapies to alter the course of neurodegenerative disorders, such as PD and Alzheimer's disease. Cerebrospinal fluid (CSF) has been extensively studied to explore biochemical alterations in subjects with neurodegenerative disorders. To investigate potential biological confounders of reported CSF levels for α-synuclein (α-Syn), amyloid-β 1-42(Aβ42) and tau protein in Parkinson's disease and related disorders, we reviewed the current literature for known factors that underlie signal variability and speculate on those that have not yet been tested. This article is part of a special issue on Parkinson disease.

Keywords
Parkinson's disease, cerebrospinal fluid biomarker, confounding, dementia, factors, neuropathology, tau-protein, α-synuclein, β-amyloid,
MeSH
alpha-Synuclein cerebrospinal fluid MeSH
Amyloid beta-Peptides cerebrospinal fluid MeSH
Biomarkers cerebrospinal fluid MeSH
Clinical Trials as Topic methods MeSH
Cognition Disorders cerebrospinal fluid diagnosis MeSH
Humans MeSH
Parkinson Disease cerebrospinal fluid diagnosis MeSH
Peptide Fragments cerebrospinal fluid MeSH
tau Proteins cerebrospinal fluid MeSH
Cerebrospinal Fluid Proteins cerebrospinal fluid MeSH
Animals MeSH
Check Tag
Humans MeSH
Animals MeSH
Publication type
Journal Article MeSH
Research Support, Non-U.S. Gov't MeSH
Review MeSH
Names of Substances
alpha-Synuclein MeSH
amyloid beta-protein (1-42) MeSH Browser
Amyloid beta-Peptides MeSH
Biomarkers MeSH
Peptide Fragments MeSH
tau Proteins MeSH
Cerebrospinal Fluid Proteins MeSH

Article

Elektroforesa bílkovin v likvoru
[Protein electrophoresis in the cerebrospinal fluid]

VYMAZAL, J
Author VYMAZAL, J

Neurologie a psychiatrie ceskoslovenska. 1955 Jul ; 18 (4) : 310-2.

Neurol Psychiatr Ceskoslov
Neurologie a psychiatrie ceskoslovenska | Neurol Psychiatr Ceskoslov
Source

Keywords
CEREBROSPINAL FLUID *, PROTEINS/in cerebrospinal fluid *,
MeSH
Electrophoresis * MeSH
Cerebrospinal Fluid * MeSH
Cerebrospinal Fluid Proteins * MeSH
Publication type
Journal Article MeSH
Names of Substances
Cerebrospinal Fluid Proteins * MeSH

Article

Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation

... AIMS: The aim of this study was to evaluate the diagnostic potential of cerebrospinal fluid (CSF) and ...

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2017 Sep ; 161 (3) : 286-295. [epub] 20170925

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
ISSN 1804-7521 | 1213-8118
Source

AIMS: The aim of this study was to evaluate the diagnostic potential of cerebrospinal fluid (CSF) and serum levels of neurocytoskeletal proteins and their ratios for the diagnosis of dementias and to assess the differences in neurocytoskeletal proteins between neurodegeneration and neuroinflammation. METHODS: CSF and serum levels of neurofilament light subunits (NFL) and neurofilament heavy subunits (NFH) as well as CSF levels of total tau (t-tau) and phosphorylated tau (p-tau) proteins were determined using ELISA in 20 Alzheimer's disease patients (AD group), 13 patients with other dementias (OD group), 17 patients with inflammatory aseptic neuro-infections (IP), and 20 aged-matched cognitively normal elderly persons (NC group). RESULTS: The ratio CSF p-tau/t-tau was significantly higher in the NC group than that in the AD or OD groups (P<0.0005 for each group). The CSF NFH/p-tau and CSF NFL/p-tau ratios were significantly lower in AD patients than OD patients (P≤0.003). Serum and CSF NFL and CSF NFH levels were significantly higher in OD patients than AD patients (P≤0.03). The lowest values of the CSF NFL/NFH ratio were found in the IP group and they significantly differed from those in normal controls (P<0.0001) and any dementia group (IP vs. AD P<0.0001; IP vs. OD P=0.03). CONCLUSION: CSF tau proteins and their index differentiated between AD or OD patients and cognitively normal subjects, while CSF levels of neurofilaments expressed as their index seem to contribute to the discrimination between patients with neuroinflammation and normal controls or AD patients.